The Novavax and Pfizer Adjuvant Platform Strategy

Pfizer has licensed Novavax's Matrix-M adjuvant for use in up to two vaccine programs, with Novavax receiving an upfront payment and eligibility for future milestones and royalties. The deal allows Pfizer to develop and commercialize vaccines using the adjuvant, while Novavax…

Listen